Physician profile
Benjamin R Strauss
NPI 1295091163
$3,856.15
in general payments reported to CMS, 2019-2025
21 companies · $1,167 in 2025
The $1,167 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $80.81 · 2021: $263 · 2022: $272 · 2023: $934 · 2024: $765 · 2025: $1,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,798 · Gift: $66.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,797.85 |
| Gift | $66.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $588.25 | 2019-2025 | Tryptyr, Rocklatan, Clareon Panoptix Pro |
| Dompe US, INC. | $499.03 | 2022-2025 | Oxervate |
| Oyster Point Pharma, INC. | $408.60 | 2022-2024 | Tyrvaya |
| Rxsight INC | $385.42 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Abbvie INC. | $329.35 | 2024-2025 | |
| Eyepoint US, INC. | $250.00 | 2019 | |
| Tearlab Corp | $201.95 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $187.84 | 2024-2025 | Xdemvy |
| Microsurgical Technology, INC. | $153.53 | 2025 | |
| Biotissue Holdings INC. | $148.66 | 2021-2024 | |
| Glaukos Corporation | $145.92 | 2023 | |
| Bausch & Lomb Americas INC. | $136.28 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $109.22 | 2024 | |
| Allergan, INC. | $76.69 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $60.54 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akorn, INC. | $53.22 | 2019 | |
| Amgen INC. | $53.02 | 2025 | Tepezza |
| Harrow Eye, LLC | $20.92 | 2024 | Vevye |
| Eyevance Pharmaceuticals LLC | $17.27 | 2021 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Strauss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.